GlassScriptPhysician profile
Jackie R Kazee
NPI 1679734693
$45,419.07
in general payments reported to CMS, 2019-2025
56 companies · $2,605 in 2025
The $2,605 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $12K · 2021: $13K · 2022: $7,424 · 2023: $5,447 · 2024: $2,441 · 2025: $2,605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,311 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,163 · Entertainment: $19.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,311.27 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,162.50 |
| Entertainment | $19.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19,703.81 | 2020-2025 | |
| Allergan, INC. | $14,060.79 | 2019-2021 | |
| Novo Nordisk INC | $1,959.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,322.76 | 2019-2025 | |
| Lilly USA, LLC | $1,270.17 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Astrazeneca Pharmaceuticals LP | $926.11 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $790.30 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $594.23 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $590.16 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $396.20 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $290.76 | 2019-2023 | Livalo, Seglentis |
| Astellas Pharma US INC | $235.47 | 2019-2025 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $201.39 | 2025 | Auvelity |
| Shield Therapeutics INC | $190.91 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $178.17 | 2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jackie Kazee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.